Quantum BioPharma Explores Myelin Protection as New Focus in MS Treatment
August 19th, 2026 5:06 PM
By: Newsworthy Staff
Quantum BioPharma's Lucid-MS targets myelin preservation to address multiple sclerosis progression independent of relapses, with Phase 2 trial clearance and PET imaging collaboration with Massachusetts General Hospital.
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing a novel approach to treating multiple sclerosis (MS) by focusing on myelin protection rather than solely suppressing the immune system. The company's lead candidate, Lucid-MS, is designed to prevent and reverse myelin degradation, the underlying mechanism of MS, offering a potential new avenue for patients who experience disability progression even without relapses.
Recent research has highlighted the role of chronic active, or “smoldering,” lesions and compartmentalized inflammation within the central nervous system as contributors to ongoing tissue damage. These processes may not be fully addressed by current therapies that primarily target peripheral immune activity. Quantum BioPharma's strategy with Lucid-MS is to directly target myelin degradation, aiming to preserve myelin and support functional recovery, which could be a paradigm shift in MS treatment.
The company has collaborated with Massachusetts General Hospital on PET imaging to assess myelin integrity, a crucial tool for monitoring treatment efficacy. Moreover, Quantum BioPharma has received clearance to begin a Phase 2 trial of Lucid-MS following Phase 1 studies that reported a favorable safety profile in healthy volunteers. This progression marks a significant milestone in the development of a therapy that could address unmet needs in MS care.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly-owned subsidiary, Lucid Psycheceuticals Inc., it is focused on the research and development of Lucid-MS, a patented new chemical entity. The company also retains ownership in Unbuzzd Wellness Inc. and receives royalty payments from sales of UNBUZZD(TM), while retaining rights to develop similar products for pharmaceutical and medical uses.
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.
Source Statement
This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,
